FKB 01MD

Drug Profile

FKB 01MD

Alternative Names: FKB01MD; TGBA 01AD

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Antidepressants
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1D receptor modulators; Serotonin 2 receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 15 Mar 2017 TGBA01AD is available for licensing. http://www.fabrekramer.com
  • 08 Jan 2016 Phase-II development for Major depressive disorder is ongoing in USA
  • 16 Nov 2011 TGBA01AD is available for licensing. http://www.fabrekramer.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top